STERIS (STE) Q4 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Julie Winter - Vice President of Investor Relations & Corporate CommunicationsMichael Tokich - Senior VP & CFODaniel Carestio - President, CEO & DirectorPatrick Wood - Managing DirectorMac Etoch - Senior Research Associate Conference Call Participants David Turkaly - Research AnalystMike Matson - Senior Equity Research AnalystMichael Polark - Senior Equity Research AnalystJason Bednar - Senior Research AnalystBrett Fishbin - Vi ...

Nayax Ltd. NYAX reported mixed results for the first quarter on Tuesday.The company posted quarterly earnings of 19 cents per share which beat the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $81.11 million which missed the analyst consensus estimate of $85.59 million.“Nayax is off to an excellent start in 2025 as we continue to execute on driving profitable topline growth, improving our recurring revenue mix, increasing our market share, and expanding our geograp ...

Advance Auto Parts (AAP) FY 2025 Annual General Meeting May 14, 2025 08:30 AM ET Speaker0 My name is Jeff Vining, and I am Advance's Executive Vice President, General Counsel and Corporate Secretary. Before we begin, be advised that our remarks today contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward looking statements, including, but not limited to, statements about our strategic ...

Summary of iRhythm (IRTC) Conference Call Company Overview - **Company**: iRhythm Technologies, Inc. (IRTC) - **Industry**: Medical Devices, specifically cardiac monitoring solutions Key Points and Arguments Q1 Performance and Guidance - Q1 revenue beat expectations by $5 million, leading to a $15 million increase in guidance for 2025 [3][4] - Achieved over 20% year-over-year growth for the second consecutive quarter, indicating strong business momentum [4][5] - The primary driver for the Q1 performance was the significant growth of the Zio AT product, which is expected to sustain through 2025 [5][6] Seasonality and Revenue Distribution - Revenue distribution for 2025 is expected to follow historical seasonality: approximately 22.5% in Q1, 25% in Q2, 25% in Q3, and 27.5% in Q4 [6][7] Competitive Landscape - iRhythm capitalized on competitive disruptions in late Q3 and Q4 of 2024, gaining new accounts [8][9] - Despite competitors returning to the market, iRhythm has maintained a significant portion of the business acquired during the disruption [9] Market Share and Product Performance - iRhythm holds a 70% market share in the Zio monitoring segment, with expectations of continued share growth [11][12] - The Zio Monitor, launched 18 months ago, has been well-received, contributing to the company's strong competitive positioning [12] Gross Margin and Tariff Impact - Gross margin guidance for the year is flat, with an anticipated negative impact of 50 to 75 basis points from tariffs, primarily affecting imports from China and Taiwan [13][14] - The company is exploring mitigation strategies to reduce tariff exposure, which may lead to gross margin expansion in 2025 [15][17] FDA Submissions and Future Products - iRhythm plans to submit the next-generation Zio MCT product for FDA approval in Q3 2025, which is expected to enhance market share [20][21] - The company aims for a faster launch of Zio MCT compared to previous product transitions [22] Primary Care Strategy - The partnership with Epic is expected to enhance clinician workflows and has already shown a 20% average volume uplift in pilot accounts [26][28] - Over one-third of Q1 volume came from primary care prescribers, up from approximately 20% in 2023, indicating a successful land-and-expand strategy [33][35] Innovative Channel Partnerships - Innovative channel partnerships are beginning to contribute to volume, with low single-digit percentages of overall volume but showing growth from near zero [37] Financial Outlook - iRhythm anticipates slightly negative free cash flow for 2025, with expectations to turn positive in 2026 [53][54] - Long-term goals include achieving 15% EBITDA margins at $1 billion in revenue, with potential for mid-20% margins beyond that [49] International Market and Reimbursement - The Japanese market remains strategically important despite disappointing reimbursement rates, with plans to generate in-country clinical evidence for future reimbursement cycles [55][57] Pricing Strategy - A low single-digit pricing headwind is expected for the year, consistent with past trends, while the company focuses on volume growth [59] Additional Important Insights - iRhythm is committed to operational excellence and efficiency improvements, leveraging automation and global infrastructure to enhance profitability [41][44] - The company is actively investing in R&D for adjacent market opportunities, including multi-sensing capabilities [50][52]

巴克莱：微软裁员行动展现出其在兑现盈利增长承诺方面的努力。 ...

据LSEG IBES数据：欧洲公司预计第一季度盈利将同比增长1.9%，一周前预期为0.4%。欧洲公司预计 第一季度收入将同比增长2.3%，一周前预期为1.9%。 ...

编号：2025-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 兆日科技2024年度业绩说明会采用网络远程方式进行，面向全体投资 者 时间 2025 年 5 月 12 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访 谈"栏目 公司接待人员 姓名 主持人：兆日科技 董事长, 总经理：魏恺言 董秘, 财务负责人：余凯 独立董事：张汉斌 独立董事：赵崴 独立董事：MAK,SAI CHAK 投资者关系活动 主要内容介绍 1.公司之后的盈利有什么增长点？ 答：您好，公司后续盈利增长点主要是传统的电子支付密码器系统以 及银行对公平台相关业务，期待纸纹防伪产品早日为公司贡献业绩。 谢谢！ 兆日科技 2024 年度业绩说明会 投资者活动记录表 证券代码：300333 证券简称：兆日科技 深圳兆日科技股份有限公司 | | 2.公司本期的盈利水平如何 | | --- | --- | | | 答：您好，报告期内， ...

[Table_Title] 研究报告 2025 年 5 月 13 日 雷诺瓦（9519 JP） 业绩稳健；2026 财年指引释放强劲盈利增长信号 Scott Darling Catherine Li 事件 尽管 RENOVA2025 财年第四季度息税折摊前利润因超预期营收表现优于一致预期，但其 2025 财年第四季度业绩仍可 能被市场视作利好。根据公司新公布的 2026 财年指引，营收、息税折摊前利润及盈利分别为 905 亿日元、316 亿日 元和 15 亿日元，仅略低于一致预期。公司项目总体进展顺利，并进一步披露了已通过最终投资决策的储能项目细 节。 点评 营收超出一致预期：RENOVA 的息税折摊前利润为 67 亿日元（一致预期约为 55 亿日元），主要受益于超预期的营 收表现。 2026 财年盈利指引低于一致预期；但盈利能力稳健提升：根据 RENOVA 公布的 2026 财年（截至 2026 年 3 月止财 年）新指引，营收为 905 亿日元（一致预期为 923 亿日元）、息税折摊前利润为 316 亿日元，同比增长 36%（一致 预期为 346 亿日元）、盈利为 15 亿日元（一致预期为 28.8 亿日 ...

一、【直播回放】 近期，上市公司2024年年报陆续公布。 有朋友问，上市公司的定期报告有哪些，在哪里查看呢？过去几年，哪些公司赚钱了，哪些亏钱了？ 上市公司盈利增长恢复了么？盈利波动变化，我们该如何投资？ 在今晚的直播课里，螺丝钉详细介绍了这些问题。 文 | 银行螺丝钉 （转载请注明出处） 长按识别下面二维码，添加 @课程小助手 微信，回复「 0509 」即可观看直播回放。 （提示：回复后可以耐心等待几秒哦～） 二、【部分直播课内容如下】 1. 上市公司定期报告 上市公司每年会有4份定期报告，分别是1季报、半年报（中报）、3季报和年报。 这些定期报告，各自的披露时间，如下表所示。 | | 上市公司每年有4份定期报告 | | --- | --- | | 1季报 | 每年的前3个月结束后一个月内，即每年的4月份， 且不得早于上一年度的年度报告披露时间。 | | 半年报（中报） | 半年度结束后2个月内，即每年的7-8月份。 | | 3季报 | 每年的前9个月结束后一个月内，即每年的10月份。 | | 年报 | 年度结束后4个月内,即每年的1-4月份。 | 这些报告中的数据，可以帮助我们观察上市公司的盈利增长情况。 ...

此前七次出现红色信号后，标普500指数在未来12个月平均下跌5.6%。当前红色周期是该模型自2022年2月以来首次发出看跌信号——当时市场对美联储加 息路径的担忧令美股陷入熊市。 很难准确判断这对标普500指数意味着什么。在经历了21个月的中性"黄色"区间后，当前红色周期对模型大多数成分指标而言仍处于初期阶段。虽然这可能 预示着更多下跌，但由于美国贸易政策难以预测，投资者仍在争论最严重的抛售是否已经结束。 "要么全球贸易战很快结束，一切自行化解;要么股市抛售加剧，投资者在情况恶化到出现买入机会前就认赔离场，"股票策略师沃尔夫在电话采访中表 示，"但目前尚未到达那个临界点。" 智通财经APP注意到，一项股市指标已进入历史数据显示与标普500指数最差回报前景相关的阶段。此前贸易紧张局势笼罩金融市场，削弱了美国企业的盈 利增长前景。 彭博行业研究的股票市场周期模型将市场划分为三个阶段——加速增长(绿色)、温和增长(黄色)和下跌(红色)。根据该机构分析师吉娜·马丁·亚当斯和吉莉安· 沃尔夫汇编的数据，该模型在今年3月和4月跌入了警示性的红色区域。 其他模型成分仅显现初步恶化迹象。例如，远期盈利预测的同比增速虽仍显著高 ...